Abstract
Cultured primary fetal cells from one organ donation could possibly meet the exigent and stringent technical aspects for development of therapeutic products. These cell types have fewer technological limitations for cellular proliferation capacity (simple culture conditions) and maintenance of differentiated phenotype, and they also have low probability for transmission of communicable diseases since they can be manufactured using traditional cell banking platforms. Master and working cell banks (MCB, WCB) can be obtained from one fetal organ donation, permitting multiple tissues (skin, bone, cartilage, muscle, and intervertebral disc) to be processed in short periods of time with identical methods to assure a stringent tracing of the processes for the production of standardized therapeutic agents. In addition, specific cell delivery systems for each tissue type can be adapted to the clinical application. Since it is the intention that banked primary fetal cells enhance the prospective treatment of hundreds of thousands of patients with only one organ donation, it is imperative to show consistency, traceability, and safety of the processes including donor tissue selection, cell banking, cell testing, and growth of cells in outscaling for the preparation of bioengineered products for clinical application.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Master Z, McLeod M, Mendez I. Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson’s disease. J Med Ethics. 2007;33:169–73.
Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol. 2004;36:568–84.
Bhattacharya N. Fetal cell/tissue therapy in adult disease: a new horizon in regenerative medicine. Clin Exp Obstet Gynecol. 2004;31:167–73.
Ricordi C, Edlund H. Toward a renewable source of pancreatic cells. Nat Biotech. 2008;26:397–8.
Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, Young H, Richardson M, Smart NG, Cunningham J, Agulnick AD, D’Amour KA, Carpenter MK, Baetge EE. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin secreting cells in vivo. Nat Biotech. 2008;26:443–5.
Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell. 2008;132:661–80.
Hohlfeld J, de Buys Roessingh A, Hirt-Burri N, Chaubert P, Gerber S, Scaletta C, Hohlfeld P, Applegate LA. Tissue-engineered fetal skin constructs for paediatric burns. Lancet. 2005;366:840–2.
de Buys Roessingh AS, Hohlfeld J, Scaletta C, Hirt-Burri N, Gerber S, Hohlfeld P, Gebbers J-O, Applegate LA. Development, characterization and use of a fetal skin cell bank for tissue engineering in wound healing. Cell Transplant. 2006;15:823–34.
Hirt-Burri N, Scaletta C, Gerber S, Pioletti DP, Applegate LA. Wound-healing gene family expression differences between fetal and foreskin cells used for bioengineered skin substitutes. Artif Organs. 2008;32:509–18.
Ramelet A-A, Hirt-Burri N, Raffoul W, Scaletta C, Pioletti DP, Offord E, Mansourian R, Applegate LA. 2008 Chronic wound healing by fetal cell therapy may be explained by differential gene profiling observed in fetal versus old skin cells. Exp Gerontol. 2009;44(3):208–18. Epub 2008 Nov 20.
Hirt-Burri N, de Buys Roessingh AS, Scaletta C, Gerber S, Pioletti DP, Applegate LA, Hohlfeld J. Human muscular fetal cells: a potential cell source for muscular therapies. Pediatr Surg Int. 2008;24:37–47.
Montjovent MO, Burri N, Mark S, Federici E, Scaletta C, Zambelli PY, Hohlfeld P, Leyvraz P-F, Applegate LA, Pioletti DP. Fetal bone cells for tissue engineering. Bone. 2004;35:1323–33.
Montjovent M-O, Mathieu L, Schmoekel H, Silke M, Bourban P-E, Zambelli P-Y, Laurent-Applegate LA, Pioletti DP. Repair of critical size defects in the rat cranium using ceramic-reinforced PLA scaffolds obtained by supercritical gas foaming. J Biomed Mater Res. 2007;83A:41–51.
Montjovent M-O, Silke M, Mathieu L, Scaletta C, Scherberich A, Delabarde C, Zambelli P-Y, Bourban P-E, Applegate LA, Pioletti DP. Human fetal bone cells associated with ceramic reinforced PLA Âscaffolds for tissue engineering. Bone. 2008;42:554–64.
Montjovent MO, Bocelli-Tyndall C, Scaletta C, Scherberich A, Martin I, Laurent-Applegate L, Pioletti DP. In vitro characterization of immune-related properties of human fetal bone cells for potential tissue engineering applications. Tissue Eng Part A. 2009;15(7):1523–32.
Quintin A, Schizas C, Scaletta C, Jaccoud S, Chapuis-Bernasconi C, Gerber S, Juillerat L, Osterheld MC, Applegate LA, Pioletti DP. Human foetal spine as a source of cells for intervertebral disc regeneration. J Biol Mol Med. 2009;13:1–12.
Pioletti DP, Montjovent MO, Zambelli P-Y, Applegate LA. Bone tissue engineering using foetal cell therapy. Swiss Med Wkly. 2006;136:557–60.
Kneser U, Schaefer DJ, Polykandriotis E, Horch RE. Tissue engineering of bone: the reconstructive surgeon’s point of view. J Cell Mol Med. 2006;10:7–19.
Bach AD, Arkudas A, Tjiawi J, Polykandriotis E, Kneser U, Horch RE, Beier JP. A new approach to tissue engineering of vascularized skeletal muscle. J Cell Mol Med. 2006;10:716–26.
Humphries C. Fetal-cell transplants reverse Parkinson’s in two patients focus online: News from Harvard Medical, Dental, and Public Health Schools. 2005. http://focus.hms.harvard.edu/2005/Jun10_2005/neurology.shtml, www.mclean.harvard.edu/pdf/news/mitn/harvardfocus.ole061005.pdf
Deierborg T, Soulet D, Roybon L, Hall V, Brundin P. Emerging restorative treatments for Parkinson’s disease. Prog Neurobiol. 2008;85:407–32.
McKay R, Kittappa R. Will stem cell biology generate new therapies for Parkinson’s disease? Neuron. 2008;58:659–61.
Zhang F, Pasumarthi KB. Embryonic stem cell transplantation: promise and progress in the treatment of heart disease. BioDrugs. 2008;22:361–74.
Bohl D, Liu S, Blanchard S, Hocquemiller M, Haase G, Heard JM. Directed evolution of motor neurons from genetically engineered neural precursors. Stem Cells. 2008;26:2564–75.
Oster H, Wilson DI, Hanley NA. Human embryo and early fetus research. Clin Gene. 2006;70:98–107.
Zimmerman RK. Ethical analyses of vaccines grown in human cell strains derived from abortion: arguments and internet search. Vaccine. 2004;22:4238–44.
Quintin A, Hirt-Burri N, Scaletta C, Schizas C, Pioletti DP, Applegate LA. Consistency and safety of cell banks for research and clinical use: preliminary analysis of fetal skin banks. Cell Transplant. 2007;16(7):675–84.ur.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Hirt-Burri, N., Applegate, L.A. (2013). Fetal Cell Therapy and Tissue Engineering for Musculoskeletal Tissues. In: Bhattacharya, N., Stubblefield, P. (eds) Human Fetal Tissue Transplantation. Springer, London. https://doi.org/10.1007/978-1-4471-4171-6_14
Download citation
DOI: https://doi.org/10.1007/978-1-4471-4171-6_14
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-4170-9
Online ISBN: 978-1-4471-4171-6
eBook Packages: MedicineMedicine (R0)